{
    "clinical_study": {
        "@rank": "93932", 
        "acronym": "INFLUENCE", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This will be prospective, multicentre, observational study. Patients who will initiate\n      treatment with IFN\u03b2-1b (Betaferon) will be followed up to 6 months. Baseline visit (visit 0)\n      i.e. treatment initiation plus four follow-up visits (visits 1-4). For each patient\n      demographics, medical history data, safety parameters, presence of flu-like symptoms and\n      measures to prevent or treat these symptoms will be collected."
        }, 
        "brief_title": "Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to McDonald\n             (2005) criteria\n\n          -  Age >/= 18 years old\n\n          -  Treatment MS patients in whom the attending physician has decided to initiate therapy\n             with interferon beta-1b; Betaferon\n\n          -  Minimum 6 months wash-out period from previous IFN\u03b2\n\n          -  Written Informed Consent signed\n\n        Exclusion Criteria:\n\n          -  Patients previously treated with any of the disease modifying drugs (DMDs), with the\n             exception of IFN\u03b2 therapy which ended at least 6 months earlier\n\n          -  Patients receiving treatment with IFN beta other than Betaferon (Bayer)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult MS patients starting Betaferon therapy"
            }
        }, 
        "enrollment": {
            "#text": "650", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706055", 
            "org_study_id": "16400", 
            "secondary_id": "BF1213PL"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.", 
            "intervention_name": "Interferon beta-1b (Betaseron, BAY86-5046)", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons", 
                "Interferon beta-1b"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis (MS)", 
            "Interferon"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Poland"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon\u00ae", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean severity score of Flu-Like Symptoms (FLS) recorded within the first 6 months following treatment initiation", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706055"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency of usage of particular pharmacological and non-pharmacological practices applied by investigators to prevent or manage FLS", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change from baseline of daily activities impairment of patients with FLS, based on patient's self assessment using four categories", 
                "safety_issue": "No", 
                "time_frame": "From baseline up to 6 months"
            }, 
            {
                "measure": "Betaferon tolerability measured as occurrence of Adverse Events (AE) and FLS over 6 months period", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "For demographic assessment the following parameters will be recorded at visit 0: birthdate (at least year), sex, weight, height.", 
                "measure": "MS patient with Flu-Like Symptoms (FLS) demographic profile.", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 month"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}